Point Of Contact Not Available

The National Institute of Allergy and Infectious Diseases (NIAID) wishes to expedite development of two classes of currently licensed and marketed drugs for treatment of potential agents of bioterrorism: (1) Antiviral drugs for treatment of viral hemorrhagic fevers, and (2) Antibiotics for treatment of anthrax, pneumonic plague, and tularemia. NIAID is interested in receiving letters of interest regarding screening, development, and future licensure from organizations that have candidate drugs and the needed research capabilities. Interested organizations should submit a letter of interest that contains a detailed description of their potential development plans, and their R&D capabilities and interest. The letter of interest along with any supporting documentation shall not exceed 10 pages. Letters of interest will be kept confidential and will help in determining the need for an RFP to support further development, testing, and licensure of these products, and in assembling a potential source list for distribution if an RFP is issued. Submit your response to Barbara Shadrick at the address listed in this Special Notice.

Bid Protests Not Available